VIA
CBIO

Virtus Investment Advisers’s Crescent Biopharma CBIO Stock Holding History

Virtus Investment Advisers’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$329K Buy
+18,258
New +$356K 0.08% 360

Other funds holding CBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $452M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Virtus Investment Advisers's CBIO Position: Q2 2026 in Review

Virtus Investment Advisers opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 18,258 shares worth $329K. The stake represents 0.08% of the portfolio and ranks #360 among its holdings.

23 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Virtus Investment Advisers held 18,258 shares of Crescent Biopharma worth $329K as of Q2 2026.
  • Crescent Biopharma was a new Virtus Investment Advisers position in Q2 2026.
  • Crescent Biopharma made up 0.08% of Virtus Investment Advisers's portfolio in Q2 2026, its #360 holding.
  • 23 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.